放射治疗在弥漫性内生性脑桥胶质瘤管理中的作用:系统综述
该系统综述检索PubMed至2018年3月,纳入49项常规分割放疗研究(1286例)、5项低分割研究(92例)和8项高分割研究(348例),比较不同放疗方案及联合系统治疗对DIPG患者生存的影响,为临床选择放疗策略提供参考。
要点
- 常规分割放疗组平均中位OS为12.0个月,高于高分割(7.9个月)和低分割(10.2个月)。
- 接受放疗增敏治疗者平均中位OS为11.5个月,未接受同期系统治疗者为9.4个月。
- 接受挽救性放疗者自初诊起平均中位OS为16.3个月。
核心结论
- 本系统综述汇总了DIPG放疗研究,常规分割放疗的平均中位OS数值最高,但需结合研究异质性解读。
研究设计与样本
- 检索PubMed至2018年3月10日,纳入报告DIPG放疗结局的前瞻性和回顾性系列研究。
- 纳入49项常规分割放疗研究(1286例)、5项低分割研究(92例)和8项高分割研究(348例)。
主要发现
- 常规分割、高分割和低分割放疗组的平均中位OS分别为12.0个月、7.9个月和10.2个月。
- 接受放疗增敏治疗者平均中位OS为11.5个月,未接受同期系统治疗者为9.4个月。
- 接受挽救性放疗者自初诊起平均中位OS为16.3个月。
关键数值与推荐
- 常规分割放疗组平均中位OS为12.0个月(49项研究,1286例)。
- 高分割放疗组平均中位OS为7.9个月(8项研究,348例)。
- 低分割放疗组平均中位OS为10.2个月(5项研究,92例)。
- 放疗增敏治疗组平均中位OS为11.5个月,未接受同期系统治疗组为9.4个月。
- 挽救性放疗组自初诊起平均中位OS为16.3个月。
临床怎么用
- 本综述汇总的放疗方案生存数据可供临床医生为DIPG患者选择放疗策略时参考。
局限性
- 纳入研究为前瞻性和回顾性系列,可能存在异质性,原文未报告具体偏倚评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diffuse intrinsic pontine glioma (DIPG) is the most aggressive primary pediatric brain tumor, with <10% of children surviving 2 years. Radiation therapy (RT) remains the mainstay of treatment, but there is a great clinical need for improvements and advancements in treatment strategies. The aim of this systematic review was to identify all available studies in which RT was used to treat patients with DIPG. METHODS AND MATERIALS: A literature search for studies published up to March 10, 2018 was conducted using the PubMed database. We identified 384 articles using search items "diffuse intrinsic pontine glioma" and 221 articles using search items "diffuse brainstem glioma radiotherapy." Included studies were prospective and retrospective series that reported outcomes of DIPG treatment with RT. RESULTS: We identified 49 studies (1286 patients) using upfront conventionally fractionated RT, 5 studies (92 patients) using hypofractionated RT, and 8 studies (348 patients) using hyperfractionated RT. The mean median overall survival (OS) was 12.0 months, 10.2 months, and 7.9 months in patients who received conventional, hyperfractionated, and hypofractionated RT regimens, respectively. Patients undergoing radiosensitizing therapy had a mean median OS of 11.5 months, and patients who did not receive concomitant systemic therapy had an OS of 9.4 months. In patients who received salvage RT, the mean median OS from initial diagnosis was 16.3 months. CONCLUSIONS: As one of the largest systematic reviews examining RT for DIPG, this report may serve as a useful tool to help clinicians choose the most appropriate treatment approach, while also providing a platform for future investigations into the utility of RT and systemic therapy.
引用
- Gallitto M, Lazarev S, Wasserman I, et al. Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review. Adv Radiat Oncol. 2019. PMID: 31360809. doi:10.1016/j.adro.2019.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。